Treatment of Gilles de la Tourette's Syndrome With Clonidine and Neuroleptics

Shapiro, Arthur M.

doi:10.1001/archpsyc.1983.01790100081011

Cited by 57 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is used more commonly in America than in Europe [195]. Case reports of clonidine’s efficacy in treating TS appeared in the early 1980s [150] and open-label trial evidence has been contradictory [45, 46, 234, 248]. A single-blind, placebo-controlled trial demonstrated a significant improvement in 6 out of 13 patients [133].…”

Section: Pharmacological Treatment Options For Tsmentioning

confidence: 99%

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

Roessner¹,

Plessen²,

Rothenberger³

et al. 2011

Eur Child Adolesc Psychiatry

389

398

View full text Add to dashboard Cite

To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.

show abstract

Section: Pharmacological Treatment Options For Tsmentioning

confidence: 99%

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

Roessner¹,

Plessen²,

Rothenberger³

et al. 2011

Eur Child Adolesc Psychiatry

389

398

View full text Add to dashboard Cite

show abstract

“…These positive results have subsequently been confirmed by several other authors (Dorsey, 1981;Shapiro et al, 1983) and clonidine has been established as one of the first line drugs in the long-term management of TS (Shapiro et al, 1983). The beneficial effect of clonidine in TS implicated central NA-ergic mechanisms in the pathophysiology of TS.…”

mentioning

confidence: 57%

“…Furthermore, clonidine has been reported to block successfully symptoms of opiate, alcohol, and barbiturate withdrawal symptoms (Aghajanian, 1982;Glassman et al, 1984) indicating a close interaction between the noradrenergic and opiatergic systems in the CNS. The two presently most effective drugs in TS, haloperidol and clonidine (Shapiro et al, 1983), have been shown to act on the endogenous opioid system. Neuroleptics have high affinity for opioid receptors, and some of the butyrophenones have greater affinity for opioid receptors than pethidine (Creese et al, 1976).…”

Section: The Opioid System In Tsmentioning

confidence: 99%

Tourette syndrome: A case for noradrenergic and opiatergic mechanisms

Sandyk

1986

International Journal of Neuroscience

View full text Add to dashboard Cite

“…Antipsychotics were more efficacious in an open trial [28] . Some have found clonidine to be as efficacious as haloperidol [29] and another pilot study has demonstrated equal efficacy with risperidone in children with de la Tourette syndrome (dTS) [30] .…”

Section: Clonidine In Dtsmentioning

confidence: 90%

Clonidine Use in Psychiatry: Panacea or Panache?

Naguy¹

2016

Pharmacology

View full text Add to dashboard Cite

Clonidine, an alpha agonist, formally prescribed in clinical medicine as antihypertensive medication, is currently being used more frequently to address a multitude of psychiatric entities. The long-acting formulation is approved by the Food and Drug Administration for use in treating the attention-deficit/hyperactivity disorder. In addition to this only legitimate indication, it has long been used successfully for opiate detoxification, post-traumatic stress disorder and de la Tourette syndrome. Moreover, clonidine helps in the treatment of neuroleptic-induced akathisia, stimulant-induced insomnia and clozapine-induced sialorrhea. It has been tried in treating menopausal syndrome and psychogenic polydipsia. Although the strength of evidence supporting the use of clonidine in such clinical scenarios is highly variable and oscillating, from strong to only flimsy, this overview is intended to shed some light on the clonidine portfolio as a potential and attractive addition to the psychopharmacologic armamentarium.

show abstract

Treatment of Gilles de la Tourette's Syndrome With Clonidine and Neuroleptics

Cited by 57 publications

References 23 publications

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment

Tourette syndrome: A case for noradrenergic and opiatergic mechanisms

Clonidine Use in Psychiatry: Panacea or Panache?

Contact Info

Product

Resources

About